Pliant Therapeutics, Inc.
PLRX Healthcare Biotechnology
Pliant Therapeutics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $1.6 million, down 83.7% from fiscal 2022. In the quarter to June 2026, EPS grew 49.3% and free cash flow grew 68.6%, each against the same quarter a year earlier.
Follow PLRX
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | |
|---|---|---|---|---|---|---|---|---|
Cash and Short Term Investments |
190.94 | 355.72 | 494.25 | 331.19 | 200.60 | 276.89 | 102.77 | 60.95 |
Receivables |
— | — | — | 2.07 | 2.08 | 9.36 | 7.39 | 0.50 |
Other current assets |
1.04 | — | — | 5.98 | 6.38 | 4.50 | 1.74 | 0.28 |
Total current assets |
196.45 | 362.26 | 505.50 | 340.31 | 209.44 | 290.75 | 111.90 | 61.73 |
Property, Plant, Equpment (Net) |
2.94 | 5.53 | 3.57 | 4.49 | 4.61 | 4.32 | 4.08 | 4.26 |
Long-term assets (Other) |
1.87 | 1.92 | 1.87 | 0.39 | 0.84 | 0.45 | 3.09 | 0.54 |
Total non-current assets |
28.78 | 34.69 | 6.65 | 10.30 | 11.77 | 4.77 | 7.16 | 4.80 |
Total Assets |
225.23 | 396.95 | 512.15 | 350.61 | 221.22 | 295.53 | 119.06 | 66.53 |
Accounts Payable |
0.48 | 5.96 | 4.53 | 1.58 | 2.97 | 2.02 | 1.25 | 2.58 |
Accrued Expenses |
14.44 | 26.72 | 22.68 | 19.88 | 11.99 | 9.58 | 6.92 | 2.51 |
Total current liabilities |
16.37 | 33.22 | 28.52 | 23.91 | 16.83 | 11.60 | 8.17 | 5.08 |
Long Term Debt (Total) |
— | 30.21 | 10.05 | 9.93 | 5.33 | — | — | — |
Non-current Liabilities (Other) |
— | — | — | — | — | 0.87 | 0.91 | 0.81 |
Total non-current liabilities |
27.66 | 59.65 | 10.05 | 13.36 | 5.33 | 0.87 | 0.91 | 0.81 |
Total liabilities |
44.02 | 92.87 | 38.58 | 37.27 | 22.16 | 12.47 | 9.08 | 5.90 |
Additional Paid In Capital |
1,040.61 | 1,013.81 | 972.97 | 653.71 | 414.35 | 400.92 | 0.00 | — |
Preferred Stock (Total) |
— | — | — | — | — | — | 186.28 | 132.10 |
Common Stock (Net) |
0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
Retained Earnings |
(859.40) | (710.05) | (499.75) | (338.41) | (215.09) | (117.83) | (76.29) | (71.47) |
Common Equity (Total) |
181.21 | 304.08 | 473.58 | 313.34 | 199.06 | 283.06 | (76.29) | (71.47) |
Shareholders Equity (Total) |
181.21 | 304.08 | 473.58 | 313.34 | 199.06 | 283.06 | 109.98 | 60.63 |
Shareholders Equity and Liabilities (Total) |
225.23 | 396.95 | 512.15 | 350.61 | 221.22 | 295.53 | 119.06 | 66.53 |
Shares (Common) |
61.45 | 60.86 | 59.92 | 48.94 | 36.08 | 35.55 | 1.85 | 1.36 |
Shares (Preferred) |
— | — | — | — | — | — | 131.86 | 105.50 |
Shareholders Equity (Tangible) |
181.21 | 304.08 | 473.58 | 313.34 | 199.06 | 283.06 | 109.98 | 60.63 |
Net Debt |
(190.94) | (325.51) | (484.19) | (321.26) | (195.27) | (276.89) | (102.77) | (60.95) |
Total Debt |
— | 30.21 | 10.05 | 9.93 | 5.33 | — | — | — |